Elevated baseline circulating platelet-to-lymphocyte ratio and survival in initial stage IV gastric cancer patients: A meta-analysis

Guoming Hu1*, Shimin Wang2, Songxiang Wang1, Liming Huang1*

1 Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China, 2 Department of Nephrology, Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China

* hgmplj@126.com (GH); shaoxinghlm@126.com (LH)

Abstract

Background

Systemic inflammatory response (SIR) plays important roles in initiation, promotion and progression of tumor. However, the prognostic role of baseline circulating platelet–to–lymphocyte ratio (PLR) (known as a marker of SIR) in human initial stage IV gastric cancer (GC) remains controversial. Hence, we performed this meta-analysis to assess the value of it in prognosis prediction for these patients.

Materials and methods

We searched PubMed, Embase and EBSCO to identify the studies and computed extracted data with STATA 12.0.

Results

A total of 3025 patients with initial stage IV GC from 13 published studies were incorporated into this meta-analysis. We found that elevated baseline circulating PLR was significantly associated with decreased overall survival (OS), but not with progression–free survival (PFS) in stage IV GC patients. However, in stratified analyses, high PLR was only associated with worse 1-year and 2-year OS, but not with 3-year or 4-year OS; In addition, it was considerably related with reduced 6-month PFS, but not with 1-year or 2-year PFS. Moreover, high PLR markedly correlated with peritoneal metastasis of GC.

Conclusion

Elevated baseline circulating PLR decreased 1-year OS and 6-month PFS in initial stage IV GC patients, implicating that it is a valuable prognostic index for these patients and modifying the inflammatory responses may have a potential for effective treatment.
Introduction

Human gastric cancer (GC) is one of the most common fatal malignancies worldwide. Although progress in early diagnosis and therapeutic strategies have benefited these patients, the advance in prognosis prediction especially in initial stage IV GC still remains poor. Recently, several systemic inflammatory response (SIR)—related hematological factors have been extensively investigated to risk-stratify cancer patients to improve treatment selection and to predict survival in many types of cancers including stage IV GC.

The platelet–to–lymphocyte ratio (PLR), known as a marker of the SIR, which can easily be measured on the basis of absolute platelets and lymphocytes in the clinical setting, has been regarded as a potential prognostic index in various cancers [1]. Previous studies have reported that circulating PLR was remarkably associated with clinical outcomes of GC patients [2, 3]. However, different stages indicate very differential survival of cancer; and SIR will also vary as tumor progresses. They haven’t clarified the association between such index and prognosis in initial stage IV GC patients in those studies. Although many researchers have investigated the value of baseline circulating PLR in prognosis prediction for stage IV GC patients, their results were not consistent even controversial [4–6]. A re-assessment is therefore warranted. Moreover, the potential of PLR in peripheral blood before treatment as an effective prognostic index and therapeutic strategy is necessary to be explored.

In this study, we performed the meta-analysis to quantitatively summarize the association between baseline circulating PLR and clinical outcomes such as overall survival (OS) and progression–free survival (PFS) in initial stage IV GC patients, and thereby provided more evidence on the clinical value of PLR as a prognostic index for these patients.

Methods

Search strategy

We searched PubMed, Embase and EBSCO for studies assessing the PLR in peripheral blood before treatment and survival in initial stage IV GC patients from 1996 to March 31th 2021. The keywords adopted for search were (“platelet to lymphocyte ratio” OR “PLR” OR “inflammation”) AND (“gastric cancer” OR “stomach cancer”) AND (“prognosis” OR “survival”). A total of 524, 836 and 1748 entries were identified in PubMed, Embase and EBSCO respectively.

Inclusion and exclusion criteria

Inclusion criteria of the meta-analysis were: studies must have (1) been published as original articles in English; (2) assessed human subjects with histopathologically diagnosed with stage IV GC; (3) provided hazard ratios (HRs) with 95% confidence interval (CI), or Kaplan–Meier curves of high and low circulating PLR before treatment with OS or PFS.

The exclusion criteria were that studies have not been published as research articles or full texts including commentary, case report and letters to editors and conference abstracts; Studies without sufficient data for hazard ratios (HRs) evaluation; studies that detected PLR not in peripheral blood or after treatment or not in stage IV disease.

Endpoints

In this meta-analysis, we recorded OS as the primary endpoint; while PFS were regarded as the second endpoint. Individual studies defined cut-offs of PLR and classified patients into high- and low- groups.
OS and PFS definition
OS was defined as the time from the date of the first curative operation to the date of the last follow-up, or death from any cause; while PFS was the time from the date of the diagnosis until progression or death from any cause.

Data extraction
Two authors (GM.H. and SX.W.) independently reviewed and extracted information including first author’s name, publication year, number of patients, median age, time of follow-up and cut-off value to determine high PLR. OS, PFS and clinicopathological data including tumor differentiation, peritoneal, liver or lung metastasis etc were extracted from the text or tables.

Quality assessment
Two independent authors adopted Newcastle–Ottawa Scale (NOS) [7] to assess the quality of individual study, and achieved consensus for each item under the help of the third or more authors. Six or above that the study scored was regarded as high quality.

Statistical analysis
Relevant data were combined into hazard ratios (HRs) for OS, PFS, and odds ratios (ORs) for clinicopathological features such as tumor differentiation, peritoneal metastasis etc with STATA 12.0 respectively based on the random-effect model if statistical heterogeneity was considerable [8], otherwise, the fixed–effect model was applied [9]. We also adopted sensitivity analysis, Begg’s funnel plot and Egger’s test [10] to determine the influence of individual study on the overall result and potential publication bias respectively. All P values were two-sided and below 0.05 was treated as statistical significance.

Results
Search results and description of studies
Flow chart diagram of study selection was exhibited in Fig 1. Thirteen studies with 3025 patients were ultimately included in this meta-analysis [4–6, 11–20]. And all these studies were scored 6 or above after careful assessment with the Newcastle–Ottawa Scale (NOS). Three studies included patients who underwent non-curative surgery with chemotherapy; One study included patients receiving chemotherapy or not, while the others included patients treated with chemotherapy alone. Four studies evaluated both OS and PFS outcomes; and eight studies evaluated only OS, whereas one study evaluated only PFS. PLR was calculated from pretreatment laboratory data in all these included studies. Characteristics of researches being appropriate for data integration were exhibited in Table 1 and S1 Table in S1 File.

Meta-analyses
Overall survival (OS). Eleven studies involving 2616 patients investigated the association between PLR and OS, and the meta-analysis exhibited that increased baseline PLR in peripheral blood notably decreased OS (HR = 1.60, 95% CI 1.41 to 1.82, P < 0.001) in patients with stage IV GC (Fig 2).

However, in stratified analyses, we noted that elevated circulating PLR before treatment was only associated with worse 1-year (OR = 0.48, 95% CI 0.36 to 0.64, P < 0.001) and 2-year
(OR = 0.61, 95% CI 0.40 to 0.95, \( P = 0.028 \)) survival, but not with 3-year (OR = 0.79, 95% CI 0.44 to 1.44, \( P = 0.451 \)) or 4-year (OR = 0.35, 95% CI 0.11 to 1.11, \( P = 0.075 \)) OS (Fig 3).

**Progression–free survival (PFS).** As for the association between PLR and PFS, five studies have supplied the relevant data. The pooled data indicated that high baseline circulating PLR was not markedly associated with reduced PFS in patients (HR = 1.19, 95% CI 0.91 to 1.55, \( P = 0.213 \)). (Fig 4) in stratified analyses, as shown in Fig 5, the results revealed that it was considerably related with worse 6-month PFS (OR = 0.55, 95% CI 0.33 to 0.92, \( P = 0.022 \)), but not with 1-year (OR = 0.48, 95% CI 0.19 to 1.21, \( P = 0.121 \)) or 2-year PFS (OR = 0.83, 95% CI 0.22 to 3.19, \( P = 0.787 \)).

**Clinicopathologic features.** We next investigated whether high baseline circulating PLR correlated with clinicopathological features, and discovered that it was considerably associated with peritoneal metastasis (OR = 1.30, 95% CI 1.04 to 1.63, \( P = 0.024 \)), but not with liver (OR = 1.41, 95% CI 0.84 to 2.39, \( P = 0.195 \)) or lung (OR = 1.03, 95% CI 0.35 to 3.04, \( P = 0.954 \)) metastasis in stage IV disease (S1A–S1C Fig in S1 File). And there was no correlation between
| Research          | Year | Patients’ No. | M / F | median age (range) (year) | Cut-off value | PLR: (H/L) | Treatment                  | median follow-up (months) | Clinical outcome | Quality Score (NOS) |
|-------------------|------|---------------|-------|---------------------------|---------------|------------|---------------------------|--------------------------|-----------------|-------------------|
| Zhao, G.H. et al. | 2020 | 110           | 84/26 | ≥65:44.55%; <65:55.45%    | ≥143.39       | 71/39      | chemotherapy              | 11.6                     | OS              | 7                 |
| Zhou, D.Y. et al. | 2020 | 537           | 216/321| 55.0 (25, 83)             | ≥284          | NR         | chemotherapy              | NR                      | OS, PFS         | 7                 |
| Wang, H. et al.   | 2020 | 466           | 327/139| ≥60:47.85%; <60:52.15%    | ≥174.79       | 233/233    | chemotherapy              | NR                      | OS, PFS         | 7                 |
| Petrillo, A. et al.| 2018| 151           | 97/54 | ≥62:51.6%; <62:48.4%      | ≥157          | 76/75      | non-curative surgery and chemotherapy | 29 (20.4, 37.5)       | OS, PFS         | 8                 |
| Huang, Z.H. et al.| 2018| 136           | 82/54 | ≥55 (28, 85)              | ≥223          | 47/89      | chemotherapy              | NR                      | PFS             | 6                 |
| Wang, J. et al.   | 2018 | 273           | 186/87| 56.68±10.73              | ≥201.6        | 67/206     | chemotherapy              | NR                      | OS              | 7                 |
| Aldemir, M.N. et al.| 2015| 50            | 30/20 | ≥65 (40, 82)              | ≥170          | 23/27      | chemotherapy              | NR                      | OS              | 7                 |
| Wang, F. et al.   | 2015 | 120           | 75/45 | ≥68 (32, 82)              | ≥235          | 60/60      | chemotherapy              | ≤40                     | OS, PFS         | 8                 |
| Wang, Q. et al.   | 2014 | 365           | 270/95| ≥50:76.7%; <50:23.3%      | ≥160          | 197/168    | chemotherapy              | NR                      | OS              | 7                 |
| Lee, S. et al.    | 2013 | 174           | 114/60| (24, 74)                  | ≥160          | 86/88      | chemotherapy              | 14.9 (1.0, 47.9)       | OS              | 7                 |
| Mimatsu, K. et al.| 2017 | 33            | 25/8  | (62.0, 79.8)              | ≥200          | 16/17      | non-curative surgery and chemotherapy | NR                      | OS              | 7                 |
| Zhai, Z. et al.   | 2021 | 306           | 245/61| 58 (28, 85)               | ≥128          | NR         | non-curative surgery and chemotherapy | 11                     | OS              | 7                 |
| Huang, C. et al.  | 2020 | 304           | 198/106| 60 (51, 67)               | ≥107.7        | 263/41     | Chemo therapy or not     | NR                      | OS              | 7                 |

PLR, platelet-to-lymphocyte ratio; M, male; F, female; OS, overall survival; PFS, progression-free survival; NR, not reported.

https://doi.org/10.1371/journal.pone.0265897.t001

Fig 2. Forest plots describing HR of the association between elevated baseline circulating PLR and OS in initial stage IV GC patients. HR: hazard ratio; GC: gastric cancer; OS: overall survival.

https://doi.org/10.1371/journal.pone.0265897.g002
PLR and tumor differentiation (OR = 1.10, 95% CI 0.82 to 1.47, \( P = 0.528 \)) of patients (S1D Fig in S1 File).

Sensitivity analysis

Sensitivity analysis demonstrated that each included research had no impact on the overall result for OS or PFS (S2 Fig in S1 File).

Publication bias

Funnel plot and Egger’s test indicated that no significant publication bias existed between combined therapy and OS (\( P = 0.239 \)) or PFS (\( P = 0.715 \)) in patients (S3 Fig in S1 File).
Fig 4. Forest plots describing HRs of the association between elevated baseline circulating PLR and PFS in initial stage IV GC patients. HR: hazard ratio; GC: gastric cancer; PFS, progression-free survival.

https://doi.org/10.1371/journal.pone.0265897.g004

Fig 5. Forest plots describing ORs of the association between elevated baseline circulating PLR and PFS at 6-month, 1-year, 2-year in initial stage IV GC patients. OR, odds ratios; GC, gastric cancer; PFS, progression-free survival.

https://doi.org/10.1371/journal.pone.0265897.g005
Discussion

Systemic inflammatory response is closely related to the initiation, promotion and progression of cancer [21]. In this study, we found that high baseline circulating PLR remarkably decreased OS in initial stage IV GC patients; However, we noted that it didn’t reduce PFS in these patients. In stratified analyses, high PLR was only associated with worse 1-year and 2-year OS, and 6-month PFS, but not with 3-year or 4-year OS, or 1-year, 2-year PFS. In addition, high PLR was considerably correlated with peritoneal metastasis of GC. These findings suggested that high baseline circulating PLR played a critical role in promoting tumor progression and metastasis of GC.

Several potential mechanisms might be responsible for the close association between increased PLR and worse prognosis. Previous researches have demonstrated that platelets play a key role in tumor progression and are associated with poor survival in patients with various types of malignancies [22]. Platelets can induce angiogenesis via the secretion of vascular endothelial growth factor (VEGF) and inhibit anti-tumor response mediated by effector T cells [23]. Platelets can also protect the circulating tumor cells (CTCs) from shearing stresses during circulation [24]. Lymphocytes have an important role in cancer immune surveillance and prevent development of malignancy [25]. The decrease in CD4+ T-helper cells may lead to a sub-optimal lymphocyte-mediated immune response to cancer cells [26]. Taken together, we observed that an increase in the platelet count or decrease in the lymphocyte count in the peripheral blood correlate with tumor initiation and progression. Hence, the PLR may help to predict prognosis and reflect the degree of tumor progression in stage IV GC. However, in this study, we noted that pre-treatment PLR correlated with worse 1-year, 2-year OS and 6-month PFS rather than 3-year, 4-year OS, and 1-year, 2-year PFS. The mechanism underlying such results needs further investigation.

Previous studies have demonstrated that Inflammatory cytokines such as IL-17A and IL-6 were closely linked with cancer associated inflammation [27]. Hence, we thought that the addition of agents (for example: IL-17A mAb, IL-6 mAb) against inflammation to the basic treatment including chemotherapy, palliative surgery etc would probably be a promising strategy for patients with initial stage IV gastric cancer.

There is a limitation that should be noted from this meta-analysis, studies with negative results might not be published, which could cause potential publication bias.

In conclusion, elevated circulating PLR before treatment leads to worse 1-year and 2-year OS and 6-month PFS in initial stage IV GC patients, implicating that it might be a valuable prognostic index and modifying the inflammatory responses may have a potential for effective treatment for these patients.

Supporting information

S1 Checklist. PRISMA 2009 checklist. (DOC)

S1 File. (DOC)

Acknowledgments

We thank all the members of the departments who helped in this study.
Author Contributions
Conceptualization: Liming Huang.
Data curation: Guoming Hu, Shimin Wang.
Formal analysis: Guoming Hu, Shimin Wang.
Investigation: Guoming Hu.
Project administration: Guoming Hu.
Supervision: Guoming Hu.
Validation: Songxiang Wang.
Writing – original draft: Guoming Hu.

References
1. Albayrak S, Zengin K, Tanik S, Atar M, Unal SH, Imamoglu MA, et al. Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer? The Kaohsiung journal of medical sciences. 2016; 32(6):327–33. https://doi.org/10.1016/j.kjms.2016.05.001 PMID: 27377847.
2. Cao W, Yao X, Cen D, Zhi Y, Zhu N, Xu L. The prognostic role of platelet-to-lymphocyte ratio on overall survival in gastric cancer: a systematic review and meta-analysis. BMC gastroenterology. 2020; 20(1):16. Epub 2020/01/22. https://doi.org/10.1186/s12876-020-1167-x PMID: 31959103; PubMed Central PMCID: PMC6971934.
3. Zhang X, Zhao W, Yu Y, Qi X, Song L, Zhang C, et al. Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis. World journal of surgical oncology. 2020; 18(1):191. Epub 2020/08/01. https://doi.org/10.1186/s12957-020-01952-2 PMID: 32731872; PubMed Central PMCID: PMC7391520.
4. Zhao G, Liu N, Wang S, Guo J, Song X, Qi Y, et al. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer. Medicine. 2020; 99(10): e19405. Epub 2020/03/10. https://doi.org/10.1097/MD.0000000000019405 PMID: 32150090; PubMed Central PMCID: PMC7478543.
5. Wang Q, Yang Y, Zhang YP, Zou Z, Qian X, Liu B, et al. Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer. Medical oncology. 2014; 31(12):289. Epub 2014/10/27. https://doi.org/10.1007/s12032-014-0289-9 PMID: 25344872.
6. Wang H, Ding Y, Li N, Wu L, Gao Y, Xiao C, et al. Prognostic Value of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Combined Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Stage IV Advanced Gastric Cancer, Frontiers in oncology. 2020; 10:841. Epub 2020/07/09. https://doi.org/10.3389/fonc.2020.00841 PMID: 32637393; PubMed Central PMCID: PMC7317009.
7. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in meta-analyses. European journal of epidemiology. 2010; 25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370.
8. Kuritz SJ, Landis JR, Koch GG. A general overview of Mantel-Haenszel methods: applications and recent developments. Annual review of public health. 1988; 9:123–60. https://doi.org/10.1146/annurev.pu.09.050188.001011 PMID: 32882229.
9. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary clinical trials. 2007; 28(2):105–14. https://doi.org/10.1016/j.cct.2006.04.004 PMID: 16807131.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997; 315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563; PubMed Central PMCID: PMC2127429.
11. Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, et al. Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. Future oncology. 2018; 14(24):2493–505. https://doi.org/10.2217/fon-2018-0167 WOS:000449031500006 PMID: 29969265.
12. Wang J, Qu J, Li Z, Che X, Liu J, Teng Y, et al. Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer.
13. Zhai Z, Gao J, Zhu Z, Cong X, Lou S, Han B, et al. The Ratio of the Hemoglobin to Red Cell Distribution Width Combined with the Ratio of Platelets to Lymphocytes Can Predict the Survival of Patients with Gastric Cancer Liver Metastasis. BioMed research international. 2021; 2021:8729869. Epub 2021/01/29. https://doi.org/10.1155/2021/8729869 PMID: 33506035; PubMed Central PMCID: PMC7814956.

14. Zhou D, Wu Y, Zhu Y, Lin Z, Yu D, Zhang T. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy. Journal of Cancer. 2020; 11(14):4205–12. Epub 2020/05/06. https://doi.org/10.7150/jca.39575 PMID: 32368303; PubMed Central PMCID: PMC7196266.

15. Mimatsu K, Fukino N, Ogasawara Y, Saino Y, Oida T. Utility of Inflammatory Marker- and Nutritional Status-based Prognostic Factors for Predicting the Prognosis of Stage IV Gastric Cancer Patients Undergoing Non-curative Surgery. Anticancer Res. 2017; 37(8):4215–22. Epub 2017/07/26. https://doi.org/10.21873/anticanres.11812 PMID: 28739709.

16. Wang F, Liu ZY, Xia YY, Zhou C, Shen XM, Li XL, et al. Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. BMC Cancer. 2018; 18(1):515. Epub 2018/05/04. https://doi.org/10.1186/s12885-018-4414-6 PMID: 29720123; PubMed Central PMCID: PMC5932840.

17. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6):883–99. https://doi.org/10.1016/j.cell.2010.01.025 PMID: 20303878; PubMed Central PMCID: PMC2866629.

18. Gu XB, Gao XS, Cui M, Xie M, Peng C, Bai Y, et al. Clinico pathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer. Oncotarget. 2016; 7(31):49876–87. https://doi.org/10.18632/oncotarget.10490 PMID: 274096652000083.

19. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. Journal of hematology & oncology. 2018;11. ARTN 125 https://doi.org/10.1016/j.jchem.2018.03.002 PubMed PMID: WOS:296571304300004.

20. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoeediting. Immunity. 2004; 21(2):137–48. https://doi.org/10.1016/j.immuni.2004.07.017 WOS:000223441900003. PMID: 15308095

21. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2010; 15(6):516–22. https://doi.org/10.3109/1354750X.2010.491557 WOS:000280976000005. PMID: 20602543

22. Chakraborty C, Sharma AR, Sharma G, Lee SS. The Interplay among miRNAs, Major Cytokines, and Cancer-Related Inflammation. Mol Ther Nucleic Acids. 2020; 20:606–20. Epub 2020/04/30. https://doi.org/10.1016/j.omtn.2020.04.002 PMID: 32348938; PubMed Central PMCID: PMC7191126.